US Stock MarketDetailed Quotes
INM InMed Pharmaceuticals
- 0.2322
- 0.00000.00%
Close Sep 27 16:00 ET
- 0.2290
- -0.0032-1.38%
Post 19:29 ET
2.07MMarket Cap-430P/E (TTM)
0.2397High0.2270Low232.84KVolume0.2270Open0.2322Pre Close53.93KTurnover2.64%Turnover RatioLossP/E (Static)8.92MShares2.080052wk High0.19P/B2.05MFloat Cap0.120752wk Low--Dividend TTM8.84MShs Float160.5000Historical High--Div YieldTTM5.47%Amplitude0.1207Historical Low0.2310Avg Price1Lot Size
About InMed Pharmaceuticals Company
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It operates through the InMed and BayMedica segments. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
Company Profile
SymbolINM
Company NameInMed Pharmaceuticals
Issue Price4.50
Founded1981
CEOMr. Eric A. Adams
MarketNASDAQ
Employees15
Fiscal Year Ends06-30
Address885 West Hastings Street,Suite 1145
CityVancouver
ProvinceBritish Columbia
CountryCanada
Zip CodeV6C 3E8
Phone1-604-669-7207
Websitehttp://www.inmedpharma.com
Company Executives
- Name
- Position
- Salary
- Eric A. Adams
- Director, President and Chief Executive Officer
- 367.57K
- Michael Woudenberg
- Chief Operating Officer
- 297.42K
- N. Netta Jagpal
- Chief Financial Officer, Corporate Secretary and Principal Accounting Officer
- --
- Alexandra D.J. Mancini
- Senior Vice President, Clinical and Regulatory Affairs
- 284.92K
- Dr. Eric C. Hsu, PhD
- Senior Vice President, Preclinical Research and Development
- --
- Andrew Hull
- Chairman of the Board
- 61.10K
- Nicole Lemerond
- Independent Director
- 46.21K
- Janet Grove
- Independent Director
- 48.60K
- Bryan T. Baldasare
- Independent Director
- 48.60K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data